Morphic Holding Surges 76% on Eli Lilly Acquisition Deal
Morphic Holding, Inc. (NASDAQ: MORF) saw a remarkable surge in premarket trading, jumping 76% to $56.15 per share following Eli Lilly’s announcement of its acquisition of the biopharmaceutical company for $3.2 billion in cash. This acquisition underscores Lilly’s strategic move to expand its portfolio in integrin therapeutics, specifically targeting inflammatory bowel diseases (IBD). Morphic Overview […]
Morphic Holding Surges 76% on Eli Lilly Acquisition Deal Read More »